
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 26 years ago
Participating Facultyalmost 26 years ago
Clinical Choices of Antibiotics: Judging Judicious Usealmost 26 years ago
Is Drug Resistance Affecting Treatment Outcomes?almost 26 years ago
Guidelines for the Management of Community-Acquired Pneumoniaalmost 26 years ago
Optimizing the Use of Antimicrobial Therapyalmost 26 years ago
Selected Abstractsalmost 26 years ago
Continuing Medical Education Quiz





